Table 2.
Top significantly enriched canonical pathways of protein coding RNAs in PVR patients
| Ingenuity canonical pathways | -log(p value) | Ratio | Molecules |
|---|---|---|---|
| Communication between innate and adaptive immune cells | 3.53 | 0.0625 | CCL3, CXCL8, IGHA1, IGHE, IGHG2, IL1B |
| Differential regulation of cytokine production in macrophages and T helper cells by IL-17A and IL-17F | 3.22 | 0.167 | CCL3, CXCL1, IL1B |
| Differential regulation of cytokine production in intestinal epithelial cells by IL-17A and IL-17F | 2.9 | 0.13 | CCL3, CXCL1, IL1B |
| Role of IL-17A in arthritis | 2.75 | 0.0727 | CXCL1, CXCL2, CXCL8, NFKBIA |
| Airway pathology in chronic obstructive pulmonary disease | 2.63 | 0.25 | CXCL2, CXCL8 |
| Glutathione-mediated detoxification | 2.48 | 0.0938 | GSTM1, GSTM4, HPGDS |
| TREM1 signaling | 2.26 | 0.0533 | CCL3, CXCL2, CXCL8, IL1B |
| Role of IL-17A in psoriasis | 2.2 | 0.154 | CXCL1, CXCL8 |
| Atherosclerosis signaling | 2.17 | 0.0397 | COL1A1, CXCL8, IL1B, PLAAT2, TPSAB1/TPSB2 |
| Role of IL-17F in allergic inflammatory airway diseases | 2.15 | 0.0714 | CXCL1, CXCL8, IL1B |